Clinical trial finds antibody-drug conjugate helps patients with metastatic non-small cell lung cancer live longer
Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement ...
Oct 26, 2023
0
1